Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

36 results about "Combination vaccines" patented technology

Combination vaccines available for many years include diphtheria and tetanus toxoids and whole-cell pertussis vaccine (DTwP); measles-mumps-rubella vaccine (MMR); and trivalent inactivated polio vaccine (IPV).

Novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof

The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Seven-component antigen African swine fever nanoparticle vaccine

The present invention belongs to the field of biotechnology, and specifically relates to a seven-component antigen African swine fever combination vaccine. The present invention first provides a seven-component antigen African swine fever nanoparticle combination composed of African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen forms a nanoparticle containing the antigen or its antigenic epitope with a nanoparticle carrier; the seven-component antigen African swine fever nanoparticle combination can stimulate the body to produce a strong immune response; secondly, the present invention prepares a vaccine comprising the above-mentioned seven-component antigen African swine fever nanoparticle combination, and the seven-component antigen African swine fever nanoparticle vaccine has a good immune protection rate against the parent African swine fever strong strain, has no biosafety risk, and breaks through the problem that the existing African swine fever subunit vaccines at home and abroad cannot provide effective immune protection for pigs.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Combination Vaccine For Prevention Of Influenza And Coronavirus Infections

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.
Owner:HOKKAIDO UNIVERSITY +1

Nucleic acid influenza vaccines and respiratory virus combination vaccines

Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.
Owner:MODERNATX INC

Veterinary vaccines against enteric diseases

PCT designated stageWO2025262123A1Bacterial antigen ingredientsAntibacterial agentsBovine rotavirusEscherichia coli
The present invention relates to a combination vaccine comprising the antigens: a) Cryptosporidium parvum gp40; b) inactivated bovine rotavirus; c) inactivated bovine coronavirus; and d) E. coli fimbrial adhesins F5 and F41. In addition, the invention relates to methods for the preparation of the vaccine, methods for vaccinating ruminants against infection by Cryptosporidium parvum, bovine rotavirus, bovine coronavirus and E. coli, and to a kit-of-parts at least comprising a container comprising the at least one antigen according to the invention.
Owner:INTERVET INT BV +1

A viral polypeptide-protein subunit combination vaccine based on DNA nanotechnology and its preparation method and application

ActiveCN117797252Bfacilitate cross-presentationimprove immunitySsRNA viruses negative-senseSsRNA viruses positive-senseDNA nanotechnologyProtein s antigen
The present invention provides a virus polypeptide-protein subunit combination vaccine based on DNA nanotechnology, and a preparation method and application thereof, belonging to the technical field of biological products. A virus polypeptide-protein subunit combination vaccine based on DNA nanotechnology uses a tetrahedral framework nucleic acid formed by DNA chain assembly as a carrier, a protein antigen that causes virus-specific T cell activation is coupled to one edge of the tetrahedral framework nucleic acid, and a virus B cell epitope peptide is coupled to the four vertices of the tetrahedral framework nucleic acid. Among all virus subunit-peptide vaccines with framework nucleic acids, coupling SARS-Cvo-2N protein to the tetrahedral framework can induce CD4 in a variety of animal models. + T cell activation can induce higher antibody titers and an increase in the ratio of memory B cells to T cells, and can also induce stronger CD8 + T cell activation provides a new idea for constructing efficient viral peptide vaccines based on protein carriers.
Owner:SHANGHAI UNIV

Combination vaccine for intradermal administration

ActiveCN114364398BBacterial antigen ingredientsAntibacterial agentsVitamin E AcetateD-alpha-Tocopheryl Acetate
The present invention relates to the field of veterinary vaccinology, specifically combination vaccines for swine. In particular, the present invention relates to a combination vaccine for protection against infection with the pathogens porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo), comprising a non-replicating immunogen for PCV2 and a non-replicating immunogen for Mhyo. The vaccine is characterized in that it is an oil-in-water emulsion comprising squalane, vitamin E acetate, and silica. In another embodiment, the present invention relates to a combination vaccine for protection against infection with the pathogens PCV2 and Mhyo by intradermal administration.
Owner:INTERVET INT BV

Combined norovirus and rotavirus vaccine composition and methods of preparation

The present invention relates to vaccine composition comprising inactivated rotavirus antigen, methods of inactivation and preparation of vaccine composition thereof. The present invention also discloses a combination vaccine comprising inactivated rotavirus antigen and norovirus antigen, and vaccine preparations thereof.
Owner:BHARAT BIOTECH INTERNATIONAL LTD

In ovo vaccine compositions against coccidiosis

PendingUS20250161424A1Protozoa antigen ingredientsViral antigen ingredientsCoccidiosisIn ovo
A composition, an in ovo vaccine, and a composition for use as a vaccine against coccidiosis. The compositions and vaccine include Eimeria oocysts from a precocious attenuated strain of E. acervulina, and from at least one precocious attenuated strain selected from E. maxima, E. praecox and E. tenella. The composition and vaccine can be administered in ovo to embryonated eggs of a domesticated bird. A combination vaccine for use in the prevention and / or treatment of an Eimeria infection and Infectious Bursal Disease (Gumboro disease) and a kit for use as a vaccine including the composition.
Owner:HIPRA SCI SLU

Streptococcus pneumoniae glycoprotein bioconjugate vaccine and methods of making and using the same

The application discloses a Streptococcus pneumoniae glycoprotein biological combination vaccine and a preparation method and application thereof. The application provides application of a recombinant plasmid with DNA molecule A and a recombinant plasmid with DNA molecule B in preparation of a Streptococcus pneumoniae vaccine; the DNA molecule A has a CPS synthesis related gene cluster of a Streptococcus pneumoniae K5 serotype; the DNA molecule B has a pglL gene and a fusion gene I; the fusion gene I comprises, from upstream to downstream, an NP gene and a gene coding a glycosylation site. In the application, the Streptococcus pneumoniae K5 serotype CPS is transferred to a carrier protein by means of a PglL system, and the obtained glycoprotein has a Streptococcus pneumoniae vaccine function. The application has important application and popularization values for prevention and control of the Streptococcus pneumoniae and treatment of diseases caused by the Streptococcus pneumoniae.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Anti-tumor combination vaccine

PCT designated stageWO2025171792A1Bacterial antigen ingredientsUnknown materialsStreptococcus pyogenesSalmonella paratyphi A
Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.
Owner:SHAOXING YUERAN BIOMEDICAL TECHNOLOGY CO LTD +1

Betacoronavirus mRNA vaccines

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

A vaccine for coronavirus and influenza virus, and method for preparation thereof

The invention discloses vaccine for coronavirus and influenza virus and method for preparation thereof. More specifically, the invention discloses seasonal viral vaccine i. e. coronavirus and influenza virus vaccine for prophylaxis of novel coronavirus (SARS-CoV-2) infection (COVID-19) and Influenza virus in mammals and method for preparation of such vaccine. The invention discloses the stable combination vaccine compositions of killed-inactivated SARS-CoV-2, Influenza virus (A and B strains) as antigens. The present invention further discloses method of adaptation and growth seasonal influenza (A and B) strains in cell culture and methods of inactivation and purification of influenza virus bulk antigen. The present invention also discloses SARS-CoV-2 vaccine formulation with inactivated Influenza viruses and use of the same to elicit immune response against the SARS-CoV-2 and Influenza viruses in mammals and humans.
Owner:BHARAT BIOTECH INTERNATIONAL LTD

Betacoronavirus MRNA vaccines

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Owner:MODERNATX INC

Recombinant plasmid and preparation method thereof, protein composition, application, vaccine and combined vaccine

The invention belongs to the field of biology, and discloses a recombinant plasmid, the recombinant plasmid comprises an expression vector and a target gene connected to the expression vector, and the target gene comprises an IFN gamma gene and a T alpha 1 gene; the nucleotide sequence of the IFN gamma gene is as shown in SEQ ID No. 1; the nucleotide sequence of the T alpha 1 gene is as shown in SEQ ID No. 2. The recombinant plasmid can significantly improve the level of an HI antibody after immunization, and the effect of the recombinant plasmid is more significant than that of a mixed preparation of a recombinant plasmid connected with an IFN gamma gene and a recombinant plasmid connected with a Talpha1 gene, which indicates that the selected specific IFN gamma gene and Talpha1 gene can generate obvious synergy after being cloned to a carrier at the same time; meanwhile, the invention further discloses a preparation method, a protein composition, application, a vaccine and a combined vaccine of the recombinant plasmid.
Owner:HUNAN AGRI UNIV

Combination vaccine

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
Owner:CUREVAC SE

Paramyxovirus combination vaccine

The present disclosure relates to a vaccine composition comprising (a) an inactivated paramyxovirus, and (b) an inactivated influenza virus. The vaccine composition may be used in methods for inducing or enhancing an immune response against an influenza infection, methods of producing the vaccine composition, and vaccine compositions produced by such methods.
Owner:GAMMA VACCINES LTD

Multivalent vaccine composition

UndeterminedLAP639AViral antigen ingredientsHepatitis B immunizationTetanus toxoids
The present invention relates to stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and Hepatitis B virus. The invention particularly provides a multivalent combination vaccine comprising of i) significantly dose reduced Salk IPV or Sabin IPV (IPV) antigens prepared by utilizing improved methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum recovery of D-antigen and ii) Injectable heat inactivated Rotavirus antigen(s) obtained from Rotavirus (CDC-9) strains that provides a broad cross-protective immunity among human rotavirus strains, iii) Hib PRP -carrier protein conjugate having improved stability and immunogenicity wherein said Hib PRP -earner protein conjugate is initially prepared by using novel conjugation process and subsequently blended at low temperature in presence of a stabilizer for minimizing free PRP release iv) whole ceil pertussis antigen with improved immunogenicity and stability obtained by addition of whole cell pertussis antigen at a later stage in a blend thereby minimizing hydrolysis based degradation v) Homogenous fractions of Diphtheria toxoid and Tetanus toxoid obtained by removal of undesirable aggregates by using Gel Permeation chromatography. The process of making such stable and immunogenic vaccine compositions by i) individually adsorbing dose reduced IPV. IRV antigens on alum hydroxide and keeping other antigen(s) unadsorbed or adsorbed on Alum Phosphate, Alum hydroxide, on a combination of Alum hydroxide and Alum phosphate and ii) using a particular order of addition of antigens during blending is also disclosed.
Owner:SERUM INST OF INDIA PTE LTD +1

BETACORONAVIRUS mRNA VACCINES

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

Betacoronavirus RNA vaccines

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to non-self-replicating RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus

The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.
Owner:ZOETIS SERVICES LLC

Virus polypeptide-protein subunit combination vaccine based on DNA nanotechnology, and preparation method therefor and use thereof

Provided are a virus peptide-protein subunit combination vaccine based on DNA nanotechnology, and a preparation method therefor and use thereof, which belong to the technical field of biological products. Provided is a virus peptide-protein subunit combination vaccine based on DNA nanotechnology, in which a tetrahedral framework nucleic acid formed by assembly of DNA strands is used as a vector, a protein antigen triggering virus-specific T cell activation is coupled to one edge of the tetrahedral framework nucleic acid, and B cell epitope peptides of a virus are coupled to four vertices of the tetrahedral framework nucleic acid.
Owner:XIANGFU LABORATORY +1

Betacoronavirus mRNA vaccines

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to mRNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

Betacoronavirus mRNA vaccines

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

A combination vaccine against erysipelothrix rhusiopathiae, porcine parvo virus and leptospira bacterium

The invention pertains to a combination of a first vaccine comprising a non-replicating immunogen of Erysipelothrix rhusiopathiae and a non-replicating immunogen of porcine parvo virus, and a second vaccine comprising a non-replicating immunogen of a Leptospira bacterium, for use in prophylactically treating a pig against an infection with Erysipelothrix rhusiopathiae, an infection with porcine parvo virus and an infection with Leptospira bacterium, by associated separate injection of the first vaccine and the second vaccine into the dermis of the pig at a first and a second injection site of that pig respectively.
Owner:INTERVET INT BV +1

CATHAY type O foot-and-mouth disease virus monoclonal antibody and its preparation kit and application

The present invention provides monoclonal antibodies 4B12 and 10G4 that specifically bind to CATHAY-type O foot-and-mouth disease virus antigens. A double-antibody sandwich kit, prepared using monoclonal antibody 4B12 as the coating antibody and enzyme-labeled monoclonal antibody 10G4 as the detection antibody, can quantitatively detect the content of CATHAY-type O foot-and-mouth disease virus virus-like particles, whether in single, multivalent, or combination vaccines, or in semi-finished or finished vaccines.
Owner:LUOYANG PULIKE WANTAI BIOTECH

BETACORONAVIRUS mRNA VACCINES

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
Owner:MODERNATX INC

Protein of RSV, PIV and / or MPV, preparation method and application of protein in preparation of combined vaccine

The invention relates to a protein comprising a protein M and / or a protein P. The protein can form a multimeric structure and is used for preparing a vaccine alone or in combination, the vaccine can stimulate a body to generate neutralizing antibodies against HMPV and / or HPIV and has broad spectrum, meanwhile, the protein has physical stability, and under physical extreme conditions, the protein can be used for preparing a neutralizing antibody against HMPV and / or HPIV. And good immunogenicity can also be maintained. When used together with an RSV vaccine, the vaccine has no mutual inhibition effect, and the immunogenicity of the vaccine can be improved.
Owner:BEIJING GENEVAX BIOTECHNOLOGY CO LTD +1